Retrospective Analysis of the Outcomes of Mycophenolate Therapy in Retarding the Progression of Immunoglobulin A Nephropathy (REMISSION IgA).

19 However, the difference in progression to ESKD between the steroid and MPA groups in our study did not reach statistical significance, echoing findings from other trials that reported mixed results regarding the benefits of steroid-sparing therapies. 20 , 21 Notably, Frisch et al . found no benefit of MMF over renin-angiotensin system inhibitors in preventing ESKD, 20 while Hou et al . reported similar remission rates with MMF and prednisone. 22 The recent MAIN trial, 23 compared mycophenolate with standard of care and concluded that 8.2% of patients in the Mycophenolate group progressed to ESKD, compared to 27.1% in the standard of care group.

also in 111,027 other papers